LACK OF ASSOCIATION BETWEEN VNTR POLYMORPHISM OF DOPAMINE TRANSPORTER GENE (SLC6A3) AND SCHIZOPHRENIA IN A BRAZILIAN SAMPLE

Quirino Cordeiro, Michael Talkowski, Joel Wood, Eliza Ikenaga, Homero Vallada

ABSTRACT - A role of dopaminergic dysfunction has been postulated in the aetiology of schizophrenia. We hypothesized that variations in the dopamine transporter gene (SLC6A3) may be associated with schizophrenia. We conducted case-control and family based analysis on the polymorphic SLC6A3 variable number tandem repeat (VNTR) in a sample of 220 schizophrenic patients, 226 gender and ethnic matched controls, and 49 additional case-parent trios. No differences were found in allelic or genotypic distributions between cases and controls and no significant transmission distortions from heterozygous parents to schizophrenic offspring were detected. Thus, our results do not support an association of the SLC6A3 VNTR with schizophrenia in our sample.

KEY WORDS: DAT1, SLC6A3, schizophrenia, genetic polymorphism, genetic association, trios.

Schizophrenia (SCZ) affects some 1% of the general population. Epidemiological studies have indicated a strong genetic component in the pathogenesis of SCZ and heritability estimates as high as 80% have been reported. Pharmacological evidence suggests an involvement of the dopaminergic system as many antipsychotic drugs block dopamine receptors in the brain and are highly effective in treating symptoms of SCZ. Further, amphetamines and cocaine tend to provoke or exacerbate psychotic symptoms in susceptible individuals by preventing dopamine re-uptake. L-DOPA has also been implicated in psychotic symptoms through variable release of dopamine into the synapse. Therefore, genes involved in the dopaminergic system are potential targets for genetic association studies with SCZ.

Polymorphisms in dopamine receptors have been widely examined, but the results have been inconclusive. Another possible candidate is the dopamine transporter gene (SLC6A3 or DAT1). The dopamine transporter (SLC6A3) plays an important role in the regulation of dopamine levels and neurotransmission by mediating the active re-uptake of synaptic dopamine back into the neurons. Two post-mortem studies on SLC6A3 binding and SCZ showed decreased striatal SLC6A3 density in chronic SCZ. A recent study using positron emission tomography found lower SLC6A3 density in sites...
in the basal ganglia, particularly in the middle third of putamen, in chronic SCZ patients than controls. This may suggest a decreased expression of SLC6A3 in a subset of chronic SCZ patients.

The SLC6A3 has been cloned and mapped to human chromosome 5 (5p15.3)\(^{17}\). A 40-bp variable number tandem repeat polymorphism (VNTR) has been reported in the 3'-untranslated region (3'-UTR) of SLC6A3, ranging from 3 to 11 copies of the repeated sequence in a non-coding region\(^{15}\). Linkage studies in SCZ pedigrees from Utah\(^{18,19}\), Italy\(^{20}\), Rouen, France, the Island of La Reunion\(^{21}\), Germany\(^{22}\), and India\(^{23}\) have all failed to demonstrate positive linkage of this VNTR to SCZ. Most of the past association studies have also reported no significant evidence for association between this SLC6A3 polymorphism and SCZ\(^{22-30}\). However, Persico and Macucci (1997) showed that the SLC6A3 genotypes in SCZ patients displayed significantly enhanced homozygote (genotypes 9/9 and 10/10) and reduced heterozygote (genotype 9/10) frequencies of the most common genotypes when contrasted with controls\(^{21}\). An association between the 10 allele and 10/10 genotype of SLC6A3 and schizoid/avoidant personality disorder has been reported in a sample of patients with distinct diagnoses, not specifically with SCZ\(^{22}\).

Thus, we report here the results of case-control and family based analyses of the SLC6A3 VNTR polymorphism in an ethnically diverse SCZ Brazilian sample.

**METHOD**

Sample

All controls, parents and schizophrenic patients provided written informed consent. The ethical approval for the study was obtained from the Ethics Committee at the Hospital das Clínicas, University of São Paulo Medical School (CAPesq).

Case-Control Study – A) Patients sample: 220 patients were recruited from inpatient and outpatient services at the Institute of Psychiatry of the Hospital das Clínicas, University of São Paulo Medical School and diagnosed according to DSM-IV\(^{33}\) criteria for SCZ.

B) Controls sample: 226 sex and ethnic matched healthy controls were recruited from the Blood Donation Service at the Hospital das Clínicas, University of São Paulo Medical School and diagnosed according to DSM-IV criteria for SCZ.

**RESULTS**

There were no significant deviations from the Hardy-Weinberg equilibrium in any of the populations for the polymorphism studied. Case-control analysis provided no evidence for allelic or genotypic association of SLC6A3 VNTR polymorphism and SCZ (Table 1). Family based analyses revealed no significant preferential transmission for any of the alleles (allele-wise TDT, \(\chi^2=5.36; 4\text{df}; p=0.25\)) or genotypes (genotype-wise TDT, \(\chi^2=5.39; 4\text{df}; p=0.24\)). When correcting our results for multiple testing we used MCE-TDT program and obtained values of \(p=0.43\) for both allelic and genotypic transmission (Table 2).

**DISCUSSION**

Past findings of post-mortem and neuroimaging studies have suggested that SLC6A3 may play a role in the pathophysiology of SCZ\(^{4,15,16}\). However, most genetic studies investigating differences in SCZ cas-

---

974 Arq Neuropsiquiatr 2004;62(4)
and controls of this VNTR polymorphism at SLC6A3 have failed to find an association with the disorder\textsuperscript{18-30}. However, one previous study has reported that the SLC6A3 genotypes in SCZ patients displayed significantly enhanced homozygote (genotypes 9/9 and 10/10) and reduced heterozygote (genotype 9/10) frequencies of the most common genotypes, maybe representing stigmata of assortative mating\textsuperscript{31}.

Thus, we conducted both case-control and family based analyses of the VNTR polymorphism in a large sample of SCZ cases as well as a smaller sample of case-parent trios. We compared the frequencies of alleles and genotypes between 220 cases and 226 controls and did not find significant differences. Our family based analysis also failed to detect linkage or association of this polymorphism with SCZ.

Distinct racial and ethnic groups display significant differences in SLC6A3 marker distributions\textsuperscript{38}. Thus, case-control association studies can potentially be underpowered to detect association in a sample of this size, particularly in the presence of ethnic admixture. This potential confound may be critical in populations of high ethnic admixture such as a Brazilian population\textsuperscript{8,39}. Therefore, we subsequently performed family based analyses of transmission distortions from heterozygous parents to SCZ offspring. This type of analysis avoids stratification biases\textsuperscript{40}. Thus, our family based analysis may provide more conclusive evidence of a lack of association at this locus with SCZ.

This finding is in accordance with most of the studies conducted to date on this polymorphism in the dopamine transporter gene. However, the SLC6A3 VNTR polymorphism may be involved in the susceptibility for other psychotic disorders, such as bipolar disorder\textsuperscript{41-43}. Further, cocaine acts on SLC6A3, enhancing the dopaminergic transmission and making this gene a strong candidate in cocaine-induced paranoia\textsuperscript{44}. Future analysis on larger populations are also required to determine if other variations in the dopamine transporter provide evidence for association to SCZ.

Acknowledgements - We would like to thank Prof. Vishwajit Nimgaonkar at the University of Pittsburgh.

REFERENCES

14. Laakso A, Bergman J, Haaparanta M et al. Decreased striatal dopamine...
transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115-120.


25. Daniels J, Williams J, Asherson P, McGuffin P, Owen M. No association between schizophrenia and polymorphisms within the genes for debriquine 4-hydroxylase (CYP2D6) and the dopamine transporter gene (DAT1) VNTR polymorphism of DAT gene and schizophrenia. Psychiatr Pol 2002;36:403-412.

